Skip to main content

Table 3 Time to progression of Endostar combined with chemotherapy versus chemotherapy alone for treating NSCLC

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

  Endostar combined with PBDC (TTP, months) PBDC alone (TTP, months) T-value 95% CI P-value
Wang JW 2005[11] 6.3 3.6 T = 12.02 1.815 to 2.91 0.000
Yang L 2005[12] 5.03 3.33    
Liu J 2009[17] 6.2 3.4    
Shi GY 2009[19] 6.1 3.7 df = 4   
Zhang H 2011[24] 7.3 5.1    
Mean ± SD 6.19 ± 0.80 3.83 ± 0.73    
  1. 95% CI, 95% confidence interval; df, degree of freedom; SD, standard deviation; TTP, time to progression.